Revenue in the second quarter increased by 1 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements.
Original Source of AstraZeneca Second Quarter and Half Year Results 2010
Nature abhors a vacuum, and apparently Novartis does, too. The Swiss drugmaker is leaping into the void created by Johnson & Johnson’s ( NYSE: JNJ ) big children’s drug recall by introducing its own children’s pain reliever and fever reducer ahead of schedule. And it’s giving the new product…
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).
Original Source of FDA Grants Priority Review to Cladribine Tablets
The U.K.’s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs–Roche’s Xeloda and MabThera, and AstraZeneca’s Iressa–which means the NHS must provide funding and resources for them in the next three months. Report
Original Source of NICE opens door to Roche, AZ cancer drugs
What do doctors really prefer: A live sales rep or a computer? According to a new survey, the human being wins–at least for primary care doctors collecting drug samples. Some 73 percent of respondents in a DTW Marketing Research study said they’d rather receive hand-delivered samples than order them…
Watch out, diabetes drugmakers–Victoza is on a roll. The Novo Nordisk ( NYSE: NVO ) drug has been racking up market-share gains in the U.S., nabbing 26 percent of the market in GLP-1 drugs since its February launch. Some 33.9 percent of new GLP scrips are going to Victoza,…
There’s a silver lining in new Medicare rules for dialysis patients for Amgen ( NASDAQ: AMGN ), which stands to lose a big chunk of sales of its IV anemia drug Epogen. And there’s a potential boost for Genzyme ( NASDAQ: GENZ ). The “bundled” payments for dialysis–which will…
It’s a one-two punch for Sanofi-Aventis: One U.S. judge reinstated an investor lawsuit over the rejected weight-loss pill Zimulti. And another refused to block generic Lovenox long enough to weigh Sanofi’s argument against its FDA approval. U.S. District Judge George Daniels decided to let Sanofi shareholders amend their Zimulti…
Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2010. In the second quarter of 2010, worldwide total revenue was $5.749 billion, an increase of 9 percent compared with the second quarter of 2009.
Original Source of Lilly Reports Strong Second-Quarter 2010 Results
Alcon’s independent directors must be grinning, now that the company has posted street-beating second-quarter earnings. Not only did the eye care company report a 15 percent jump in Q2 profits, but also hiked its outlook for the full year. That’s giving ammunition to the directors fighting for a higher…